212 related articles for article (PubMed ID: 20393293)
1. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
Schmucker C; Ehlken C; Hansen LL; Antes G; Agostini HT; Lelgemann M
Curr Opin Ophthalmol; 2010 May; 21(3):218-26. PubMed ID: 20393293
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
Mitchell P
Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.
Schmucker C; Loke YK; Ehlken C; Agostini HT; Hansen LL; Antes G; Lelgemann M
Br J Ophthalmol; 2011 Mar; 95(3):308-17. PubMed ID: 20971791
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
[TBL] [Abstract][Full Text] [Related]
6. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
7. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
[TBL] [Abstract][Full Text] [Related]
11. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
Małgorzata F
Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
Fong DS; Custis P; Howes J; Hsu JW
Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
15. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab.
Karagiannis DA; Mitropoulos P; Ladas ID
Ophthalmologica; 2009; 223(4):279-82. PubMed ID: 19390227
[TBL] [Abstract][Full Text] [Related]
16. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
17. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
[TBL] [Abstract][Full Text] [Related]
19. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
Shah AR; Del Priore LV
Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]